BerandaPHS • FRA
add
Photocure ASA
Tutup sebelumnya
€4,18
Rentang hari
€4,22 - €4,22
Rentang tahun
€4,01 - €6,13
Rasio P/E
-
Hasil dividen
-
Berita pasar
NVDA
3,22%
0,35%
0,97%
Keuangan
Laporan Pendapatan
Pendapatan
Laba bersih
(NOK) | Sep 2024info | Perubahan Y/Y |
---|---|---|
Pendapatan | 120,22Â jt | 11,79% |
Biaya operasional | 114,55Â jt | 9,62% |
Laba bersih | -3,47Â jt | 27,61% |
Margin laba bersih | -2,88 | 35,28% |
Penghasilan per saham | -0,13 | 27,78% |
EBITDA | 5,03Â jt | 50,58% |
Tarif pajak efektif | 29,87% | — |
Neraca
Total aset
Total liabilitas
(NOK) | Sep 2024info | Perubahan Y/Y |
---|---|---|
Investasi tunai jangka pdk | 291,05Â jt | 14,11% |
Total aset | 720,47Â jt | 2,11% |
Total liabilitas | 220,74Â jt | -6,73% |
Total ekuitas | 499,73 jt | — |
Saham yang beredar | 27,11 jt | — |
Harga terhadap nilai buku | 0,23 | — |
Tingkat pengembalian aset | -0,76% | — |
Tingkat pengembalian modal | -1,05% | — |
Arus Kas
Perubahan kas bersih
(NOK) | Sep 2024info | Perubahan Y/Y |
---|---|---|
Laba bersih | -3,47Â jt | 27,61% |
Kas dari operasi | 34,53Â jt | 298,30% |
Kas dari investasi | 2,43Â jt | 196,27% |
Kas dari pembiayaan | -12,90Â jt | -28,49% |
Perubahan kas bersih | 24,06Â jt | 718,75% |
Arus kas bebas | 25,14Â jt | 5.846,43% |
Tentang
Photocure ASA is a Norwegian specialty pharma company that develops and sells pharmaceuticals and medical devices based on proprietary photodynamic technology. Photocure's strategy in cancer is to continue the commercialization of Hexvix for bladder cancer diagnostics, and continue the development of the cancer portfolio and out-license prior to phase III studies. This strategy is based on a strong platform of intellectual property in photodynamic therapy. Wikipedia
Didirikan
1993
Situs
Karyawan
102